Classification of breast cancer based on the clinical immunohistochemistry (IHC) status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) is fundamental in clinical subtyping, prognostication, and treatment selection. This evidence concerns the gene ERBB2 and breast cancer.